| TGFβ signaling in growth control, cancer, and heritable disorders J Massagué, SW Blain, RS Lo Cell 103 (2), 295-309, 2000 | 3325 | 2000 |
| Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma W Hugo, JM Zaretsky, LU Sun, C Song, BH Moreno, S Hu-Lieskovan, ... Cell 165 (1), 35-44, 2016 | 3283 | 2016 |
| Mutations associated with acquired resistance to PD-1 blockade in melanoma JM Zaretsky, A Garcia-Diaz, DS Shin, H Escuin-Ordinas, W Hugo, ... New England Journal of Medicine 375 (9), 819-829, 2016 | 3180 | 2016 |
| Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation R Nazarian, H Shi, QI Wang, X Kong, RC Koya, H Lee, Z Chen, MK Lee, ... Nature 468 (7326), 973-977, 2010 | 2673 | 2010 |
| Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion R Straussman, T Morikawa, K Shee, M Barzily-Rokni, ZR Qian, J Du, ... Nature 487 (7408), 500-504, 2012 | 2015 | 2012 |
| Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression A Garcia-Diaz, DS Shin, BH Moreno, J Saco, H Escuin-Ordinas, ... Cell reports 19 (6), 1189-1201, 2017 | 1822 | 2017 |
| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E) PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ... Nature 480 (7377), 387-390, 2011 | 1695 | 2011 |
| Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma M Krauthammer, Y Kong, BH Ha, P Evans, A Bacchiocchi, JP McCusker, ... Nature genetics 44 (9), 1006-1014, 2012 | 1370 | 2012 |
| Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ... Cancer discovery 7 (2), 188-201, 2017 | 1254 | 2017 |
| RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors F Su, A Viros, C Milagre, K Trunzer, G Bollag, O Spleiss, JS Reis-Filho, ... New England Journal of Medicine 366 (3), 207-215, 2012 | 1221 | 2012 |
| Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy H Shi, W Hugo, X Kong, A Hong, RC Koya, G Moriceau, T Chodon, R Guo, ... Cancer discovery 4 (1), 80-93, 2014 | 1100 | 2014 |
| Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance H Shi, G Moriceau, X Kong, MK Lee, H Lee, RC Koya, C Ng, T Chodon, ... Nature communications 3 (1), 724, 2012 | 841 | 2012 |
| Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma J Müller, O Krijgsman, J Tsoi, L Robert, W Hugo, C Song, X Kong, ... Nature communications 5 (1), 5712, 2014 | 750 | 2014 |
| A Smad transcriptional corepressor D Wotton, RS Lo, S Lee, J Massagué Cell 97 (1), 29-39, 1999 | 720 | 1999 |
| A structural basis for mutational inactivation of the tumour suppressor Smad4 Y Shi, A Hata, RS Lo, J Massagué, NP Pavletich Nature 388 (6637), 87-93, 1997 | 655 | 1997 |
| Non-genomic and immune evolution of melanoma acquiring MAPKi resistance W Hugo, H Shi, LU Sun, M Piva, C Song, X Kong, G Moriceau, A Hong, ... Cell 162 (6), 1271-1285, 2015 | 646 | 2015 |
| Therapy-induced tumour secretomes promote resistance and tumour progression AC Obenauf, Y Zou, AL Ji, S Vanharanta, W Shu, H Shi, X Kong, ... Nature 520 (7547), 368-372, 2015 | 518 | 2015 |
| Determinants of specificity in TGF-β signal transduction YG Chen, A Hata, RS Lo, D Wotton, Y Shi, N Pavletich, J Massagué Genes & development 12 (14), 2144-2152, 1998 | 510 | 1998 |
| Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4 A Hata, RS Lo, D Wotton, G Lagna, J Massagué Nature 388 (6637), 82-87, 1997 | 505 | 1997 |
| Ubiquitin-dependent degradation of TGF-β-activated Smad2 RS Lo, J Massagué Nature cell biology 1 (8), 472-478, 1999 | 487 | 1999 |
